Department of Obstetrics and Gynecology, Erciyes University, Kayseri, Turkey.
Contraception. 2011 Nov;84(5):508-11. doi: 10.1016/j.contraception.2011.03.002. Epub 2011 Apr 15.
A prospective randomized trial was conducted to compare the clinical efficacy of two oral contraceptives containing drospirenone in the treatment of hirsutism in women.
Fifty women with moderate to severe hirsutism were recruited. Three women were lost to follow-up. Twenty-four patients received oral 0.03 mg ethinyl estradiol and 3 mg drospirenone 21/7 regimen (Group 1) for 6 months. Another group of 23 patients received oral 0.02 mg ethinyl estradiol and 3 mg drospirenone 24/4 regimen (Group 2) for 6 months. Hirsutism was assessed after 6 months using the Ferriman-Gallwey (F-G) scoring system. Hormonal levels after 6 months of both therapies were compared with baseline values and each other.
An improvement in the F-G scores for hirsutism (mean±SD) was observed in Group 1 (17.3±5.2 to 8.7±2.5, p<.001) and in Group 2 (17.5±4.8 to 7.9±2.8, p<.001). Pre- and post-treatment hirsutism scores were comparable between the groups (p>.05). Total and free testosterone levels decreased significantly after the therapy in both groups. The sex hormone-binding globulin levels increased significantly in both groups during the 6-month period.
The treatment of hirsutism with both combined oral contraceptives (COCs) containing drospirenone offered comparable effects and was well tolerated.
一项前瞻性随机试验比较了两种含有屈螺酮的口服避孕药治疗女性多毛症的临床疗效。
招募了 50 名中重度多毛症女性。3 名患者失访。24 名患者接受口服 0.03 毫克炔雌醇和 3 毫克屈螺酮 21/7 方案（第 1 组）治疗 6 个月。另一组 23 名患者接受口服 0.02 毫克炔雌醇和 3 毫克屈螺酮 24/4 方案（第 2 组）治疗 6 个月。6 个月后使用 Ferriman-Gallwey（F-G）评分系统评估多毛症。比较两种治疗方案 6 个月后激素水平与基线值和彼此之间的差异。
第 1 组（17.3±5.2 至 8.7±2.5，p<.001）和第 2 组（17.5±4.8 至 7.9±2.8，p<.001）的 F-G 多毛症评分均有改善。两组治疗前后的多毛症评分无差异（p>.05）。两组治疗后总睾酮和游离睾酮水平均显著下降，治疗期间两种球蛋白水平均显著升高。
两种含有屈螺酮的复方口服避孕药（COC）治疗多毛症效果相当，且耐受性良好。
